Business
Change of Adviser
Change of Adviser.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n RNS Number : 0938U\n Faron Pharmaceuticals Oy\n 27 July 2020\n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n (\"Faron\" or the \"Company\")\n \n \n \n \n \n Change of Adviser\n \n \n \n \n \n Company announcement, 27 July 2020 at 9.00 AM (EET)\n \n \n \n \n \n \n TURKU - FINLAND, 27 July 2020\n \n \n \n \n - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, is pleased to announce that Cairn Financial Advisers LLP has been appointed as Nominated Adviser to the Company with immediate effect. Panmure Gordon (UK) Limited continues to act as the Company's Broker.\n \n \n \n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n Dr Markku Jalkanen, Chief Executive Officer\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Cairn Financial Advisers LLP, Nomad\n \n \n Sandy Jamieson , Tony Rawlinson, Jo Turner, Mark Rogers\n \n \n Phone. +44 207 213 0880\n \n \n \n \n \n \n \n \n \n \n \n \n \n Panmure Gordon (UK) Limited, Broker\n \n \n Freddy Crossley, James Stearns\n \n \n Phone: +44 207 886 2500\n \n \n \n \n \n \n \n \n \n \n \n \n \n Sisu Partners Oy, Certified Adviser on Nasdaq First North\n \n \n Juha Karttunen, Jussi Majamaa\n \n \n Phone: +358 (0)40 555 4727\n \n \n \n \n \n \n \n \n \n \n \n \n \n Consilium Strategic Communications\n \n \n Mary-Jane Elliott, David Daley, Lindsey Neville\n \n \n Phone: +44 (0)20 3709 5700\n \n \n E-mail: \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Stern Investor Relations, Inc.\n \n \n Julie Seidel\n \n \n Phone: +(1)212 362 1200\n \n \n Email: \n \n \n [email protected]\n \n \n \n \n \n \n \n About Faron Pharmaceuticals Ltd\n \n \n Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and...